Contact this trialFirst, we need to learn more about you.
Adjuvant Therapy for Endometrial Cancer
Recruiting1 awardPhase 2 & 3
Toronto
This trial tests new treatments for endometrial cancer based on the cancer's genetic makeup. Patients are grouped by their cancer type and given tailored treatments combining radiation, chemotherapy, and targeted drugs. The aim is to find the most effective and least harmful treatments for each specific type of endometrial cancer. Dostarlimab has shown promising results in treating endometrial cancer, with a trial curing 100% of CRC patients without severe adverse events.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service